Welcome to our dedicated page for Entrada Therapeutics news (Ticker: TRDA), a resource for investors and traders seeking the latest updates and insights on Entrada Therapeutics stock.
Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a new class of medicines known as Endosomal Escape Vehicle (EEV™)-therapeutics. Founded in 2016 by 5AM Ventures, Entrada aims to make previously inaccessible intracellular targets reachable, thereby opening new avenues for treating serious diseases.
Entrada Therapeutics is pioneering the delivery of a wide range of therapeutics to various organs and tissues, thereby improving the therapeutic index. The company's portfolio includes programs targeting neuromuscular diseases, immunological disorders, and metabolic conditions, amongst others.
One of the company's most promising candidates is ENTR-601-44, which is being developed to treat Duchenne muscular dystrophy (DMD), particularly in patients who are exon 44 skipping amenable. The ongoing Phase 1 clinical trial for ENTR-601-44 aims to evaluate the safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers. This trial has already enrolled its first participants, with data anticipated in the second half of 2024.
Recent Achievements:In recent news, Entrada Therapeutics received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and the Research Ethics Committee (REC) to conduct its Phase 1 clinical trial of ENTR-601-44. Additionally, the company reported robust financial results for the third quarter of 2023, with significant cash reserves and collaboration revenue marking crucial steps in their growth trajectory.
Strategic Milestones:Entrada Therapeutics is well-positioned to continue its strategic initiatives through 2025, thanks to its strong financial footing and ongoing collaborations. The company has also recently appointed Nathan J. Dowden as President and Chief Operating Officer, further strengthening its executive team.
Beyond its lead program, Entrada's pipeline includes several other candidates aimed at treating various subtypes of DMD and myotonic dystrophy type 1 (DM1). These developments underscore Entrada's commitment to advancing its modular EEV platform to address a broad spectrum of unmet medical needs.
For more detailed and up-to-date information about Entrada Therapeutics, please visit their official website and follow them on LinkedIn.
Entrada Therapeutics (Nasdaq: TRDA), a clinical-stage biopharmaceutical company, announced a $100 million registered direct offering. The purchase involves 3,367,003 shares of common stock and pre-funded warrants to purchase an equal amount of common stock. The offering price per share is $14.85, while the pre-funded warrants are priced slightly lower at $14.8499 due to a minimal exercise price of $0.0001 per warrant. The offering is led by a U.S. healthcare investor, two global mutual funds, and Janus Henderson Investors. The funds will support ongoing clinical trials, research, and other corporate needs. The transaction is expected to close around June 25, 2024, subject to customary conditions.
Entrada Therapeutics (Nasdaq: TRDA) has reported positive preliminary data from its Phase 1 trial ENTR-601-44-101 for Duchenne Muscular Dystrophy (DMD). The drug, ENTR-601-44, was well tolerated, showing no serious adverse events. Significant plasma and muscle concentrations were observed, suggesting a clinically meaningful starting dose for Phase 2 trials. The trial included 32 healthy male volunteers, with doses ranging from 0.75 mg/kg to 6 mg/kg. The study demonstrated statistically significant exon skipping in the highest dose cohort, with plans for regulatory filings for Phase 2 trials in Q4 2024.
Entrada Therapeutics, a clinical-stage biopharmaceutical company listed on Nasdaq as TRDA, announces its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. CEO Dipal Doshi will present in a fireside chat scheduled for June 10, 2024, at 4:00 p.m. ET in Miami, FL. The session will be webcast live on the company's website, with a replay available for 90 days.
Entrada Therapeutics (Nasdaq: TRDA), a clinical-stage biopharmaceutical company focused on developing medicines targeting intracellular areas, announced its CEO, Dipal Doshi, will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will occur on May 20, 2024, at NASDAQ in New York, NY, starting at 9:30 a.m. Eastern Time. A live webcast and a 90-day replay will be accessible on the company's website.
Entrada Therapeutics, a clinical-stage biopharmaceutical company, reported its financial results for the first quarter of 2024. The company is focused on developing new medicines targeting intracellular targets. They achieved significant milestones, including dosing for the fourth cohort of a Phase 1 trial for DMD and receiving a $75 million payment from Vertex. With $327 million in cash, the company expects its cash runway to extend through 2026. Collaboration revenue increased to $59.1 million, while R&D expenses rose to $28.6 million.
FAQ
What is the current stock price of Entrada Therapeutics (TRDA)?
What is the market cap of Entrada Therapeutics (TRDA)?
What is Entrada Therapeutics' core business?
What is ENTR-601-44?
What recent milestones has Entrada Therapeutics achieved?
What is the aim of the ongoing clinical trial for ENTR-601-44?
Who founded Entrada Therapeutics?
What diseases does Entrada Therapeutics aim to treat?
How is Entrada Therapeutics funded?
Who is the current CEO of Entrada Therapeutics?
Where can I find more information about Entrada Therapeutics?
What is the significance of the EEV™ platform?
